IDXX Idexx Laboratories
A best-in-class vet diagnostics moat, but the price assumes more growth than the franchise likely delivers.
The story
IDEXX is the dominant global franchise in companion-animal diagnostics. It runs a razor/razorblade model in which a large installed base of in-clinic analyzers drives high-margin, recurring consumables, reference-lab and software revenue (over 90% recurring). Its moat comes from switching costs, its installed-base scale and its integrated cloud software. Pet ownership trends and rising diagnostic intensity per vet visit keep the reinvestment runway long. IDEXX is a mature but still compounding franchise: growth has slowed from post-COVID highs to high single digits because vet visit volumes are soft, while pricing and new platforms (inVue Dx, Cancer Dx) offset that softness.
Year-1 growth of about 9.5% combines mid-single-digit price increases, installed-base expansion and new menu items against flat to declining clinic visits. It sits slightly above the 5-year CAGR because of the inVue and Cancer Dx launches. Margins drift up from 32% to 34% through operating leverage on consumables and software, not beyond. Incremental sales-to-capital of 2.5 exceeds the historical 1.86 because growth is now consumables-led and needs less capital. A 13-year horizon fits a durable moat with a long runway, and terminal growth of 4% stays below the 4.93% risk-free rate. The market price still embeds more optimism than these drivers support.
Value drivers
| Revenue growth (Y1) | 9.5% |
| Terminal growth | 4.0% |
| Forecast horizon | 13y |
| Target operating margin | 34.0% |
| Years to target margin | 5 |
| Sales-to-capital | 2.50 |
| Beta | 0.95 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 9.1% |
| Terminal WACC | 9.3% |
Valuation bridge
| PV of explicit FCFF | 13.18B |
| PV of terminal value | 13.36B |
| Equity value | 25.61B |
| ÷ shares → per share | $325.07 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 4.99B | 9.5% | 32.5% | 1.30B | 173.02M | 1.12B | 1.03B |
| 2 | 5.44B | 9.0% | 32.9% | 1.43B | 180.32M | 1.25B | 1.05B |
| 3 | 5.90B | 8.6% | 33.2% | 1.57B | 186.66M | 1.38B | 1.06B |
| 4 | 6.38B | 8.1% | 33.6% | 1.72B | 191.85M | 1.53B | 1.08B |
| 5 | 6.87B | 7.7% | 34.0% | 1.87B | 195.74M | 1.67B | 1.08B |
| 6 | 7.37B | 7.2% | 34.0% | 2.00B | 198.15M | 1.81B | 1.07B |
| 7 | 7.86B | 6.8% | 34.0% | 2.14B | 198.92M | 1.94B | 1.05B |
| 8 | 8.36B | 6.3% | 34.0% | 2.27B | 197.93M | 2.08B | 1.03B |
| 9 | 8.85B | 5.8% | 34.0% | 2.41B | 195.06M | 2.21B | 1.01B |
| 10 | 9.32B | 5.4% | 34.0% | 2.54B | 190.22M | 2.35B | 979.51M |
| 11 | 9.78B | 4.9% | 34.0% | 2.66B | 183.35M | 2.48B | 947.93M |
| 12 | 10.22B | 4.5% | 34.0% | 2.78B | 174.43M | 2.60B | 913.38M |
| 13 | 10.63B | 4.0% | 34.0% | 2.89B | 163.48M | 2.73B | 876.23M |
Key risks
- A sustained decline in vet clinic visits that erodes volume growth and pricing power
- Competitive pressure from Zoetis, Antech/Mars and point-of-care entrants on instrument placements and consumables pricing
- Multiple compression: at roughly 38x earnings, any growth deceleration reprices the stock sharply
Catalysts
- Faster inVue Dx placements and Cancer Dx adoption that lift recurring revenue per clinic
- A recovery in clinic visit volumes combined with continued 5-6% price realization